RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma.
Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
HCC的发展常伴随广泛的代谢紊乱。单细胞RNA测序(scRNA-seq)通过分析单个细胞群体,有助于更好地理解复杂肿瘤微环境中的细胞行为。
采用癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)数据研究HCC中的代谢通路。应用主成分分析(PCA)和均匀流形近似与投影(UMAP)分析鉴定出六种细胞亚群,即T/NK细胞、肝细胞、巨噬细胞、内皮细胞、成纤维细胞和B细胞。进行基因集富集分析(GSEA)以探索不同细胞亚群之间是否存在通路异质性。基于scRNA-seq和bulk RNA-seq数据集,采用单因素Cox分析筛选与TCGA-LIHC患者总生存期差异相关的基因,并采用LASSO分析选择显著预测因子纳入多因素Cox回归。应用连接图谱(CMap)分析风险模型的药物敏感性以及高危人群中潜在化合物的靶向性。
TCGA-LIHC生存数据分析揭示了与HCC预后相关的分子标志物,包括MARCKSL1、SPP1、BSG、CCT3、LAGE3、KPNA2、SF3B4、GTPBP4、PON1、CFHR3和CYP2C9。通过qPCR比较了11个预后相关差异表达基因(DEGs)在正常人肝细胞系MIHA和HCC细胞系HCC-LM3及HepG2中的RNA表达。来自基因表达谱交互分析(GEPIA)和人类蛋白质图谱(HPA)数据库的结果显示,HCC组织中KPNA2、LAGE3、SF3B4、CCT3和GTPBP4蛋白表达较高,而CYP2C9和PON1蛋白表达较低。风险模型的靶点化合物筛选结果表明,巯嘌呤是一种潜在抗HCC药物。
与肝细胞亚群中糖脂代谢变化相关的预后基因,以及肝脏恶性肿瘤细胞与正常肝细胞的比较,可能有助于深入了解HCC的代谢特征和肿瘤相关基因的潜在预后生物标志物,并有助于为个体制定新的治疗策略。
The development of HCC is often associated with extensive metabolic disturbances. Single cell RNA sequencing (scRNA-seq) provides a better understanding of cellular behavior in the context of complex tumor microenvironments by analyzing individual cell populations.
The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data was employed to investigate the metabolic pathways in HCC. Principal component analysis (PCA) and uniform manifold approximation and projection (UMAP) analysis were applied to identify six cell subpopulations, namely, T/NK cells, hepatocytes, macrophages, endothelial cells, fibroblasts, and B cells. The gene set enrichment analysis (GSEA) was performed to explore the existence of pathway heterogeneity across different cell subpopulations. Univariate Cox analysis was used to screen genes differentially related to The Overall Survival in TCGA-LIHC patients based on scRNA-seq and bulk RNA-seq datasets, and LASSO analysis was used to select significant predictors for incorporation into multivariate Cox regression. Connectivity Map (CMap) was applied to analysis drug sensitivity of risk models and targeting of potential compounds in high risk groups.
Analysis of TCGA-LIHC survival data revealed the molecular markers associated with HCC prognosis, including MARCKSL1, SPP1, BSG, CCT3, LAGE3, KPNA2, SF3B4, GTPBP4, PON1, CFHR3, and CYP2C9. The RNA expression of 11 prognosis-related differentially expressed genes (DEGs) in normal human hepatocyte cell line MIHA and HCC cell lines HCC-LM3 and HepG2 were compared by qPCR. Higher KPNA2, LAGE3, SF3B4, CCT3 and GTPBP4 protein expression and lower CYP2C9 and PON1 protein expression in HCC tissues from Gene Expression Profiling Interactive Analysis (GEPIA) and Human Protein Atlas (HPA) databases. The results of target compound screening of risk model showed that mercaptopurine is a potential anti-HCC drug.
The prognostic genes associated with glucose and lipid metabolic changes in a hepatocyte subpopulation and comparison of liver malignancy cells to normal liver cells may provide insight into the metabolic characteristics of HCC and the potential prognostic biomarkers of tumor-related genes and contribute to developing new treatment strategies for individuals.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。